Type I '' type I toxin-antitoxin system Type I toxin-antitoxin systems rely on the
base-pairing of complementary antitoxin
RNA with the toxin
mRNA. Translation of the mRNA is then inhibited either by degradation via
RNase III or by occluding the
Shine-Dalgarno sequence or
ribosome binding site of the toxin mRNA. Often the toxin and antitoxin are encoded on opposite strands of DNA. The
5' or
3' overlapping region between the two genes is the area involved in
complementary base-pairing, usually with between 19–23 contiguous base pairs. Toxins of type I systems are small,
hydrophobic proteins that confer toxicity by damaging
cell membranes. Type I systems sometimes include a third component. In the case of the well-characterised
hok/sok system, in addition to the
hok toxin and
sok antitoxin, there is a third gene, called
mok. This
open reading frame almost entirely overlaps that of the toxin, and the translation of the toxin is dependent on the translation of this third component. Type II toxin-antitoxin systems are generally better-understood than type I. which has been found through
bioinformatics searches to represent between 37 and 42% of all predicted type II loci. The proteins are typically around 100
amino acids in length, whereas toxins from the MazF family are endoribonucleases that cleave cellular mRNAs, tRNAs or rRNAs at specific
sequence motifs. The most common toxic activity is the protein acting as an
endonuclease, also known as an
interferase. One of the key features of the TAs is the autoregulation. The antitoxin and toxin protein complex bind to the operator that is present upstream of the TA genes. This results in repression of the TA operon. The key to the regulation are (i) the differential translation of the TA proteins and (ii) differential proteolysis of the TA proteins. As explained by the "
Translation-reponsive model", the degree of expression is inversely proportional to the concentration of the repressive TA complex. The TA complex concentration is directly proportional to the global translation rate. The higher the rate of translation more TA complex and less transcription of TA mRNA. Lower the rate of translation, lesser the TA complex and higher the expression. Hence, the transcriptional expression of TA operon is inversely proportional to translation rate. A third protein can sometimes be involved in type II toxin-antitoxin systems. in the case of the ω-ε-ζ (omega-epsilon-zeta) system, the omega protein is a
DNA binding protein that negatively regulates the transcription of the whole system. Other toxin-antitoxin systems can be found with a
chaperone as a third component. This chaperone is essential for proper
folding of the antitoxin, thus making the antitoxin addicted to its cognate chaperone.
Example systems Type III Type III toxin-antitoxin systems rely on direct interaction between a toxic protein and an RNA antitoxin. The toxic effects of the protein are neutralised by the RNA gene.
Crystallographic analysis of ToxIN has found that ToxN inhibition requires the formation of a trimeric ToxIN complex, whereby three ToxI monomers bind three ToxN monomers; the complex is held together by extensive protein-RNA interactions.
Type IV Type IV toxin-antitoxin systems are similar to type II systems, because they consist of two proteins. Unlike type II systems, the antitoxin in type IV toxin-antitoxin systems counteracts the activity of the toxin, and the two proteins do not necessarily interact directly. DarTG1 and DarTG2 are type IV toxin-antitoxin systems that modify DNA. Their toxins add ADP-ribose to guanosine bases (DarT1 toxin) or thymidine bases (DarT2 toxin), and their antitoxins remove the toxic modifications (NADAR antitoxin from guanosine and DarG antitoxin from thymidine).
Type V ghoST is a type V toxin-antitoxin system, in which the antitoxin (GhoS) cleaves the
ghoT mRNA. This system is regulated by a type II system,
mqsRA.
Type VI socAB is a type VI toxin-antitoxin system that was discovered in
Caulobacter crescentus. The antitoxin, SocA, promotes degradation of the toxin, SocB, by the
protease ClpXP.
Type VII Type VII has been proposed to include systems
hha/tomB,
tglT/takA and
hepT/mntA, all of which neutralise toxin activity by post-translational chemical modification of amino acid residues.
Type VIII Type VIII includes the system
creTA. In this system, the antitoxin
creA serves as a guide RNA for a CRISPR-Cas system. Due to incomplete complementarity between the
creA guide and the
creAT promoter, the Cas complex does not cleave the DNA, but instead remains at the site, where it blocks access by RNA polymerase, preventing expression of the
creT toxin (a natural instance of
CRISPRi). When expressed, the
creT RNA will sequester the rare arginine codon tRNAUCU, stalling translation and halting cell metabolism. ==Biotechnological applications==